Posted on Leave a comment

Rheumatoid Arthritis Pipeline Assessment 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Treatment Market, Growth Prospects, and Companies by DelveInsight

Rheumatoid Arthritis Pipeline Assessment 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Treatment Market, Growth Prospects, and Companies by DelveInsight
Rheumatoid Arthritis pipeline

Rheumatoid Arthritis pipeline report including 120+ key companies and 120+ Rheumatoid Arthritis treatment therapies, analyses DelveInsight

(Albany, USA) “Rheumatoid Arthritis Pipeline Insight 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market. 

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

 

To know more about the Rheumatoid Arthritis Pipeline Analysis, click here: Rheumatoid Arthritis Pipeline Insight

 

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:

  • Rheumatoid Arthritis Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
  • Rheumatoid Arthritis companies working in the treatment market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others, are developing therapies for the Rheumatoid Arthritis treatment.
  • Emerging Rheumatoid Arthritis therapies such as TS152, HS-016, SM03, SHR0302, RC18, Otilimab, NI-0101, MBS2320, KN019, JTE-051, Interleukin 2, HL237, GLPG3970, Elsubrutinib, CKD-506, Branebrutinib, AZD9567, ATI-450, ABX464, ABBV 3373, ABBV 154, AP1189, F8IL10, AMT-101, GS-9876, CR 6086, LY 3462817, KPL-404, Orticumab, Rabeximod, YRA 1909, VIB4920, Varicella Zoster Vaccine, TAS5315, SKI-O-703, SAN-300, PF-06650833, Nipocalimab, CF-101, A223, IRL 201805, LNK 01001, PRTX-100, hUC-MSC infusion, HB-adMSC, LABP-104, VAY736, TJ003234 , SYN060, GS-5718, PF-06835375, Nivolumab, MH004, ORTD-1, ART-I02, FB704A, Amilo 5MER, CKD-374 , CFZ-533, BAY 1830839, AMG 570, JNJ-4703, CT-P47, BZ068, Invossa, LABP-69, ICM-203-R, NX-5948, KT-474 , Clarithromycin/clofazimine/rifabutin (RHB-104), Research programme: small molecule TYK2 inhibitors, MRx0006, CV6 1271, VYN201, MYMD-1, BBI 02, Research Programme: Immune mediated diseases, Foralumab, SPU-21, SFA002, NTR-441, Research programme: autoimmune disease therapeutics, AT_1001, MSB11456, MabionCD20, DMB-3113, GB232, GBS 005, TX17, BX 2922, Cinnora, AVT02, MYL-1401A, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
  • On January 2024, Rise Therapeutics LLC announced results of a Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients with Rheumatoid Arthritis.
  • On March 2024, Sonoma Biotherapeutics, Inc announced results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis.
  • On March 2024, Lynk Pharmaceuticals Co., Ltd announced results of a Randomized, Double-blind Study to Compare LNK01001 to Placebo in Adults with Rheumatoid Arthritis (RA) on a Stable Dose of csDMARDs Who Have an Inadequate Response or Intolerance to bDMARDs.
  • On February 2024, Eli Lilly and Company announced results of an Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.
  • On April 2024, AbbVie announced results of a Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).
  • On March 2024, AstraZeneca announced results of a Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants.

 

Rheumatoid Arthritis Overview:

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, stiffness, and potential joint damage and deformity over time. It occurs when the immune system mistakenly attacks the body’s own tissues, particularly the synovium—the lining of the membranes that surround the joints. Rheumatoid arthritis commonly affects smaller joints like those in the hands and feet, but it can also impact larger joints and other organs. Rheumatoid arthritis Symptoms often fluctuate in severity and can include fatigue, joint swelling, and reduced range of motion. Early Rheumatoid arthritis diagnosis and aggressive treatment are vital in managing Rheumatoid arthritis to slow disease progression, alleviate symptoms, and preserve joint function. Rheumatoid arthritis Treatment typically involves a combination of medications (such as disease-modifying anti-rheumatic drugs and biologics), physical therapy, lifestyle modifications, and sometimes surgery to repair or replace severely damaged joints.

 

DelveInsight’s Rheumatoid Arthritis Report covers around 120+ products under different phases of clinical development like

  • Late-stage Rheumatoid Arthritis products (Phase III)
  • Mid-stage Rheumatoid Arthritis products (Phase II)
  • Early-stage Rheumatoid Arthritis product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Rheumatoid Arthritis Route of Administration

 

Request for free sample Report here @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:

  • TS152: Taisho Pharmaceutical
  • SM03: SinoMab
  • SHR0302: Jiangsu Hengrui Medicine
  • RC18: RemeGen
  • Otilimab: GlaxoSmithKline
  • ATI-450: Aclaris Therapeutics
  • MBS2320: Modern Biosciences
  • PF-06651600: Pfizer
  • Obefazimod: Abivax
  • ABBV-154: AbbVie
  • Branebrutinib: Bristol Myers Squibb
  • KPL-404: Kiniksa Pharmaceuticals
  • ORTD-1: Oryn Therapeutics
  • MRx0006: 4D pharma plc.
  • LABP-69: Landos Biopharma, Inc
  • BZ068: Biozeus
  • And Many Others.

 

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis report to learn more about the emerging Rheumatoid Arthritis therapies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Rheumatoid Arthritis Pipeline Analysis

The Rheumatoid Arthritis pipeline report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Rheumatoid Arthritis Treatment.
  • Rheumatoid Arthritis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Rheumatoid Arthritis market.

The Rheumatoid Arthritis therapeutics report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Rheumatoid Arthritis therapies and drugs @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Key companies in the Rheumatoid Arthritis Therapeutics Market:

Some of the Rheumatoid Arthritis Companies working in the market are Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others.

 

Request for Sample PDF Report to know in detail about Rheumatoid Arthritis clinical trial advancements @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

 

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Rheumatoid Arthritis Current Treatment Patterns

4. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Rheumatoid Arthritis Late Stage Products (Phase-III)

7. Rheumatoid Arthritis Mid-Stage Products (Phase-II)

8.  Rheumatoid Arthritis Early Stage Products (Phase-I)

9.  Pre-clinical Products and Discovery Stage Products

10. Inactive Rheumatoid Arthritis Products

11. Dormant Rheumatoid Arthritis Products

12. Rheumatoid Arthritis Discontinued Products

13. Rheumatoid Arthritis Product Profiles

14. Key Companies in the Rheumatoid Arthritis Market

15. Key Products in the Rheumatoid Arthritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Rheumatoid Arthritis Unmet Needs

18. Rheumatoid Arthritis Future Perspectives

19. Rheumatoid Arthritis Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services